Rentschler Biopharma: New COO

CDMO Rentschler Biopharma has appointed Christiane Bardroff as Chief Operating Officer (COO), effective December 1, 2022.

Bardroff will head clinical and commercial manufacturing, engineering and technology operations, as well as production automation.

With more than 15 years of experience in the biopharmaceutical industry, mainly in large corporations, with a focus on operations and automation, including overall responsibility for the construction of new biotechnology plants, she brings extensive knowledge to her position.

Bardroff joined Rentschler Biopharma as SVP Client Program Management in February 2022 and, since May 2022, has also been SVP Clinical and Commercial Manufacturing at the Laupheim site. Previously, she was responsible for the construction of Teva Biotech’s large-scale biotechnology production facility in Ulm, Germany. In this role, she led the site leadership team and was part of Teva Biotech’s global leadership team as well.

During her many years at Roche, she gained strong experience in the production of various biotechnology products, as well as in automation, IT and project management.

Bardroff studied biotechnology and chemical engineering at Emden University of Applied Sciences, Germany and Zhejiang University of Science and Technology in Hangzhou, China.

Rentschler has sites in Laupheim, Germany; Milford, US; and Stevenage, UK.